Most recent articles by:
- Advertisement -![]( "Author Cloud Template - Life News 1")
![]( "Author Cloud Template - Life News 1")
- R&D
Research finds Merck’s treatment of lung disease can lower chance of death
Mohsin Riaz - 0Merck has released that its drug, Winrevair, reduced the risk of death in patients suffering from a rare condition that causes high blood pressure...GSK Responds to Pfizer’s RSV Approval with Data Aiming for Similar Approval in Younger Adults
Two early-phase study trials suggest that GSK’s RSV vaccine, Arexvy, may benefit certain high-risk subgroups of younger adults and could potentially serve a broader...Developments in RNA Research Win Nobel Prizes for the Second Consecutive Year
After last year’s Nobel Prize in Physiology or Medicine was awarded to Drew Weissman and Katalin Karikó for their work on mRNA vaccines, which...Long-Term Immunotherapy Benefits For Melanoma Shown in Ten-Year Survival Data
Two medications have been shown to drastically alter the prognosis for the fatal skin disease melanoma, according to information gained through a decade of...
- Clinical
Corcept’s ALS Modulator Fails to Meet Primary Endpoint in Phase 2 Study
After Amylyx and PTC, Corcept has also decided to withdraw from the amyotrophic lateral sclerosis (ALS) space. Results from its Phase 2 study, designed...BioAge Halts Phase 2 Obesity Study Just Two Months After IPO
BioAge Labs, a recent success in the biotechnology IPO market, has made a surprising decision to discontinue its phase 2 obesity study, just weeks...Novartis Shells Out $1B Upfront to PTC For Midphase Huntington Program
Novartis has paid out $1 billion upfront for worldwide rights to PTC Therapeutics' mid-phase Huntington's disorder study, facilitating the biotech's swift turnaround from unsatisfactory...Novocure’s Wearable Therapy Shows Promise in Treating Pancreatic Cancer, Phase 3 Results Reveal
As part of a first-line treatment for patients with inoperable pancreatic adenocarcinoma—one of the most lethal forms of cancer—Novocure's wearable therapy has demonstrated its...
- Commercial
Ro Partners With Eli Lilly to Offer Zepbound, a Weight-Loss Medication, in Single-Dose Vials
Ro, a direct-to-consumer health and wellness company, has announced a partnership with Eli Lilly to provide discounted single-dose vials of the weight-loss medication Zepbound....Carisma to undergo staff and clinical candidate restructuring to stretch cash reserves
Carisma, a Philadelphia-based biotech company, is undergoing significant restructuring to extend its cash reserves into the third quarter of next year. As part of...GE HealthCare to Acquire Japanese Radiopharmaceutical Business
Likely to be effective next year, GE HealthCare will assume full control of Nihon Medi-Physics (NMP), a Japanese diagnostic radiopharmaceuticals and molecular imaging agents...
- Technology
Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances
Common conditions in women such as PCOS, menopause, and endometriosis often lead to hormonal imbalances, resulting in irregular weight patterns. Wisp’s new weight care...PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm
Health technology company PicnicHealth has launched a new product, Virtual Site, which allows researchers to carry out clinical trials remotely. This innovation is targeted...Elon Musk Announces Neuralink’s Second Brain-Computer Chip Implantation in a Patient
Neuralink, founded by Elon Musk, revealed that it has placed its device in the second human trial subject. The therapeutic application of the technology...AI Firm Formation Bags $372 Series D Funding
In 2024, megarounds have been extremely uncommon. Nonetheless, Formation Bio was able to secure a remarkable series D funding round of $372 million as...
- Insights
The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption
A new independent survey of senior US pharma regulatory professionals suggests that commitment to AI investment is much higher than might be expected, although...Improving life science R&D outcomes with AI
Ben Sidders - 0Maximizing the potential AI/data-driven model of drug discovery requires the technology’s full integration into R&D. Biorelate’s Dr Ben Sidders explains. Pharma R&D latest disruption is...The medical device sector’s surging regulatory burden: how are suppliers coping?
Regulators around the world are increasing their scrutiny of medical devices as these become more critical to patient outcomes. Referencing new research, Peter Muller...The Future of Gene Therapies: Three Trends
“Maps don’t show you where you will go in life, they show you where you might go.”—John Green Over...
- Podcast
- Awards
- More
- R&D
Research finds Merck’s treatment of lung disease can lower chance of death
Mohsin Riaz - 0Merck has released that its drug, Winrevair, reduced the risk of death in patients suffering from a rare condition that causes high blood pressure...GSK Responds to Pfizer’s RSV Approval with Data Aiming for Similar Approval in Younger Adults
Two early-phase study trials suggest that GSK’s RSV vaccine, Arexvy, may benefit certain high-risk subgroups of younger adults and could potentially serve a broader...Developments in RNA Research Win Nobel Prizes for the Second Consecutive Year
After last year’s Nobel Prize in Physiology or Medicine was awarded to Drew Weissman and Katalin Karikó for their work on mRNA vaccines, which...Long-Term Immunotherapy Benefits For Melanoma Shown in Ten-Year Survival Data
Two medications have been shown to drastically alter the prognosis for the fatal skin disease melanoma, according to information gained through a decade of...
- Clinical
Corcept’s ALS Modulator Fails to Meet Primary Endpoint in Phase 2 Study
After Amylyx and PTC, Corcept has also decided to withdraw from the amyotrophic lateral sclerosis (ALS) space. Results from its Phase 2 study, designed...BioAge Halts Phase 2 Obesity Study Just Two Months After IPO
BioAge Labs, a recent success in the biotechnology IPO market, has made a surprising decision to discontinue its phase 2 obesity study, just weeks...Novartis Shells Out $1B Upfront to PTC For Midphase Huntington Program
Novartis has paid out $1 billion upfront for worldwide rights to PTC Therapeutics' mid-phase Huntington's disorder study, facilitating the biotech's swift turnaround from unsatisfactory...Novocure’s Wearable Therapy Shows Promise in Treating Pancreatic Cancer, Phase 3 Results Reveal
As part of a first-line treatment for patients with inoperable pancreatic adenocarcinoma—one of the most lethal forms of cancer—Novocure's wearable therapy has demonstrated its...
- Commercial
Ro Partners With Eli Lilly to Offer Zepbound, a Weight-Loss Medication, in Single-Dose Vials
Ro, a direct-to-consumer health and wellness company, has announced a partnership with Eli Lilly to provide discounted single-dose vials of the weight-loss medication Zepbound....Carisma to undergo staff and clinical candidate restructuring to stretch cash reserves
Carisma, a Philadelphia-based biotech company, is undergoing significant restructuring to extend its cash reserves into the third quarter of next year. As part of...GE HealthCare to Acquire Japanese Radiopharmaceutical Business
Likely to be effective next year, GE HealthCare will assume full control of Nihon Medi-Physics (NMP), a Japanese diagnostic radiopharmaceuticals and molecular imaging agents...
- Technology
Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances
Common conditions in women such as PCOS, menopause, and endometriosis often lead to hormonal imbalances, resulting in irregular weight patterns. Wisp’s new weight care...PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm
Health technology company PicnicHealth has launched a new product, Virtual Site, which allows researchers to carry out clinical trials remotely. This innovation is targeted...Elon Musk Announces Neuralink’s Second Brain-Computer Chip Implantation in a Patient
Neuralink, founded by Elon Musk, revealed that it has placed its device in the second human trial subject. The therapeutic application of the technology...AI Firm Formation Bags $372 Series D Funding
In 2024, megarounds have been extremely uncommon. Nonetheless, Formation Bio was able to secure a remarkable series D funding round of $372 million as...
- Insights
The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption
A new independent survey of senior US pharma regulatory professionals suggests that commitment to AI investment is much higher than might be expected, although...Improving life science R&D outcomes with AI
Ben Sidders - 0Maximizing the potential AI/data-driven model of drug discovery requires the technology’s full integration into R&D. Biorelate’s Dr Ben Sidders explains. Pharma R&D latest disruption is...The medical device sector’s surging regulatory burden: how are suppliers coping?
Regulators around the world are increasing their scrutiny of medical devices as these become more critical to patient outcomes. Referencing new research, Peter Muller...The Future of Gene Therapies: Three Trends
“Maps don’t show you where you will go in life, they show you where you might go.”—John Green Over...
- Podcast
- Awards
- More
Editor Picks
Acacia Pharmaceutical to be acquired by Eagle Pharma in new deal
Acacia Pharma Group is set to be acquired by Eagle Pharmaceuticals, with...
Lilly’s Jaypirca leads the leukemia trail with FDA approval
In the highly competitive landscape of BTK inhibitors for blood cancer treatment,...
GE HealthCare to Acquire Japanese Radiopharmaceutical Business
Likely to be effective next year, GE HealthCare will assume full control of Nihon...
Must Read
Ro Partners With Eli Lilly to Offer Zepbound, a Weight-Loss Medication, in Single-Dose Vials
Ro, a direct-to-consumer health and wellness company, has announced a partnership with Eli Lilly...
FDA Identifies Further Safety Concerns With Intercept’s Liver Drug
The Food and Drug Administration (FDA) has uncovered additional safety concerns related to a...
Corcept’s ALS Modulator Fails to Meet Primary Endpoint in Phase 2 Study
After Amylyx and PTC, Corcept has also decided to withdraw from the amyotrophic lateral...
About Us
Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.
Contact us: reachout(at)lifescivoice.com